Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin)
Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin)
复制标题
DOI：
10.1086/313669
复制
发表时间：
2000-02-01
影响因子：
11.8
通讯作者：
Kauffman, CA
中科院分区：
文献类型：
--
作者：
McNeil, SA;Clark, NM;Kauffman, CA
耐万古霉素屎肠球菌 (VRE) 作为医院感染日益常见的原因，引起了人们对新型抗菌药物开发的新兴趣[1]。奎奴普汀-达福普汀（Synercid，Rhône-Poulenc Rorer，巴黎）是 2 种化学性质不同的链阳菌素的组合，链阳菌素 A（达福普汀）和链阳菌素 B（奎奴普汀），可协同抑制细菌蛋白质合成 [2]。 Synercid对大多数耐药葡萄球菌、链球菌和肺炎球菌具有杀菌活性；似乎对屎肠球菌具有抑菌作用；对粪肠球菌没有活性 [2, 3]。利奈唑胺（Pharmacia & Upjohn，皮斯卡塔韦，新泽西州）是一种恶唑烷酮类似物，是第一种抑制细菌蛋白质合成的新型抗菌药物。利奈唑胺对革兰氏阳性菌具有抑菌活性，包括万古霉素耐药菌株屎肠球菌和粪肠球菌 [4, 5]。
The emergence of vancomycin-resistant Enterococcus faecium (VRE) as an increasingly common cause of nosocomial infections has spurred renewed interest in the development of novel antimicrobial agents [1]. Quinupristin-dalfopristin (Synercid, Rhône-Poulenc Rorer, Paris) is a combination of 2 chemically distinct streptogramins, streptogramin A (dalfopristin) and streptogramin B (quinupristin), which act synergistically to inhibit bacterial protein synthesis [2]. Synercid has bactericidal activity against most drug-resistant staphylococci, streptococci, and pneumococci; appears to be bacteriostatic against E. faecium; and is not active against Enterococcus faecalis [2, 3]. Linezolid (Pharmacia & Upjohn, Piscataway, NJ) is an oxazolidinone analogue, the first of a novel antimicrobial class that inhibits bacterial protein synthesis. Linezolid demonstrates bacteriostatic activity against gram-positive organisms, including vancomycin-resistant strains of E. faecium and E. faecalis [4, 5].